Cutaneous Adverse Reactions Induced by Gefitinib (Iressa) in Lung Cancer Patients |
Yun, Sook Jung
(Department of Dermatology, Chonnam National University Hwasun Hospital)
Lee, Jee Bum (Department of Dermatology, Chonnam National University Hwasun Hospital) Kim, Kyu Sik (Department of Internal Medicine, Chonnam National University Hwasun Hospital) Kim, Young Chul (Department of Internal Medicine, Chonnam National University Hwasun Hospital) |
1 | Bae EY, Kim MY, Kim HO, Park YM. A case of paronychia, acneiform eruption and dry skin induced bu Iressa. Korean J Dermatol 2004;42:665-8 |
2 | Lee MW, Seo CW, Kim SW, Yang HJ, Lee HW, Choi JH, et al. Cutaneous side effects in non-small cell inhibitor of epidermal growth factor. Acta Derm Venereol 2004:84:23-6 |
3 | Kimyai-Asadi A, Jih MH. Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors. Arch Dermatol 2002;138:129-31 DOI ScienceOn |
4 | Kris M, Natale RB, Herbst R, Lynch TJ Jr, Prager D, Belani CP, et al. Efficacy of geftinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA 2003;290:2149-58 DOI ScienceOn |
5 | Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD 1839 in skin from cancer patients: histopathologic and molecular consquencies of receptor inhibition. J Clin Oncol 2002;20:110-24 DOI ScienceOn |
6 | van Doorn R, Kirtschig G, Scheffer E, Stoof TJ, Giaccone G. Follicular and epiermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002;147:598-601 DOI ScienceOn |
7 | Forsythe B, Faulkner K. Overview of the tolerability of geftinib (IRESSA) monotherapy: clinical experience in non-small-cell lung cancer. Drug Saf 2004;27: 1081-92 DOI ScienceOn |
8 | Ranson M, Wardell S. Geftinib, a novel, orally administered agent for the treatment of cancer. J Clin Pharm Ther 2004;29:95-103 DOI ScienceOn |
9 | Kim YJ, Hwang KC, Yu DS, Oh CH, Song HJ. A case of acneiform skin eruption associated with ZD1839 (Iressa). Korean J Dermatol 2004;42:478-81 |
10 | Yu DK, Suh DH, Youn JI. A case of hair change and acneiform eruption induced by ZD1839 (Iressa). Korean J Dermatol 2004;42:1461-5 |
11 | Jang YH, Choi JH, Lim YH, Lee ES. Study of clinical features of cutaneous side effects associated with ZD 1839. Korean J Dermatol 2005;43:22-8 |
12 | Jacot W, Bessis D, Jorda E, Ychou M, Fabbro M, Pujol JL, et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumors. Br J Dermatol 2004;151: 238-41 DOI ScienceOn |
13 | Arteaga CL, Johnson DH. Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr Opin Oncol 2001; 13:491-8 DOI ScienceOn |
14 | Segaert S, van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005;16:1425-33 DOI ScienceOn |
15 | Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, et. al. Phase II study trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21:1980-7 DOI ScienceOn |
16 | Mohamed MK, Ramalingam S, Lin Y, Gooding W, Belani CP. Skin rash and good performance status predict improved survival with geftinib in patients with advanced non-small cell lung cancer. Ann Oncol 2005;16:780-5 DOI ScienceOn |
17 | Park JH, Oh JJ, Choi YL, Kim WS, Lee JH, Lee ES. Cutaneous adverse effects associated with Iressa (Geftinib) medication. Korean J Dermatol 2005;43: 92-5 |
18 | Peus D, Hamacher L, Pittelkow MR. EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentiation. J Invest Dermatol 1997;109:751-6 DOI ScienceOn |